ARDELYX, INC.
ARDX · XNASCIK 1437402fmd_0XQ86XA8QZ3000S8A21ZJ7PR8SManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2012 to Sep 30, 2026, 56 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | 42 | 3 | 5 | 8 | 10 | 52 | 124 | 334 | 407 |
| Cost of revenue | – | 8 | 0 | 1 | 0 | 1 | 4 | 18 | 51 | 40 |
| Gross profit | – | 34 | 2 | 5 | 7 | 9 | 48 | 107 | 283 | 368 |
| Research and development | 94 | 75 | 69 | 72 | 65 | 91 | 35 | 36 | 52 | 72 |
| Selling, general and administrative | – | – | – | – | – | 72 | 77 | 134 | 259 | 337 |
| Total operating expenses | 113 | 99 | 93 | 96 | – | – | – | – | – | – |
| Operating income | (113) | (65) | (91) | (91) | (91) | (154) | (64) | (63) | (28) | (41) |
| Interest expense | – | – | 4 | 6 | 5 | 5 | 3 | 5 | 13 | 20 |
| Other non-operating income (expense) | 1 | 2 | 3 | 2 | 2 | 1 | 2 | 7 | 9 | 9 |
| Income before taxes | (112) | (63) | (91) | (95) | (94) | (158) | (67) | (66) | (39) | (61) |
| Income tax expense | – | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| Net income from continuing operations | – | (64) | (91) | (95) | (94) | (158) | (67) | (66) | (39) | (62) |
| Net income | (112) | (64) | (91) | (95) | (94) | (158) | (67) | (66) | (39) | (62) |